Skip to main content

Akoya Biosciences Reports First Quarter 2024 Financial Results

MARLBOROUGH, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2024.

Business Highlights

  • Revenue was $18.4 million in the first quarter of 2024, compared to $21.4 million in the prior year period; a decrease of 14%. Reagents and services revenue continued to increase.
  • Akoya announced the establishment of a new Manufacturing Center of Excellence in Marlborough, Massachusetts to scale internal reagent manufacturing to meet the accelerating demand for reagents.
  • Akoya’s partner Acrivon Therapeutics presented initial positive Phase 2b clinical data for the ACR-368 therapeutic in patients positive for the ACR-368 OncoSignature Assay in ovarian and endometrial cancer, deployed on the PhenoImager HT platform.
  • Akoya and NeraCare, a leading developer of laboratory tests for the prognosis of melanoma patients, announced an exclusive partnership to enable personalized therapy selection for early-stage melanoma patients at high risk of relapse and death.
  • Akoya and Shanghai KR Pharmtech announced that the KR-HT5 instrument, based on the PhenoImager HT, has received premarket approval from China’s National Medical Products Administration (NMPA).

“While we made meaningful progress in advancing both our operational and clinical objectives, our first quarter results fell short of expectations due to three main factors. First, systemic pressure on capital expenditures persisted. Second, certain pharmaceutical partner lab services revenue were deferred to the second half of 2024 due to revised clinical trial milestones. Third, the completion and launch of our fully operational Manufacturing Center of Excellence temporarily impacted reagent fulfillment times, delaying instrument purchases,” said Brian McKelligon, CEO of Akoya Biosciences. “With the industry’s leading installed base, normalization of pharmaceutical partner revenue in the second half of 2024, and now resolved reagent availability issues, we believe that our foundational initiatives will lead us back to strong top-line growth and achievement of our profitability objectives.”

First Quarter 2024 Financial Results

  • Revenue was $18.4 million in the first quarter of 2024, compared to $21.4 million in the prior year period; a decrease of 14%. Reagents and services revenue continued to increase.
  • For the first quarter of 2024, reported gross margin was 46% while non-GAAP adjusted gross margin was 57% when excluding the write off from discontinued legacy instruments. Both GAAP and non-GAAP adjusted gross margin were 57% for the first quarter of 2023.
  • For the first quarter of 2024, operating expenses were $30.0 million and non-GAAP operating expenses were $25.6 million when excluding an impairment charge for facility consolidation and restructuring associated with a reduction in force in January. Both GAAP and non-GAAP operating expenses were $29.7 million for the first quarter of 2023.
  • For the first quarter of 2024, loss from operations was $21.6 million and non-GAAP loss from operations was $15.2 million, excluding the items noted above. Both GAAP and non-GAAP loss from operations were $17.4 million for the first quarter of 2023.
  • Ended the quarter with an instrument installed base of 1,213 (354 PhenoCyclers, 859 PhenoImagers), a year-over-year increase of 22% compared to an installed base of 992 in the prior year period (273 PhenoCyclers, 719 PhenoImagers).
  • 1,307 total publications citing Akoya’s technology as of March 31, 2024, compared to 860 total publications in the prior year period: an increase of 52%.
  • $61.6 million of cash, cash equivalents and marketable securities as of March 31, 2024.

2024 Financial Outlook

Akoya is updating its revenue outlook for the full year 2024 while maintaining its commitment to achieving operating cash flow breakeven by year end. The Company now expects full year 2024 revenue to be in the range of $104.0-$112.0 million.

Webcast and Conference Call Details

Akoya will host a conference call today, May 13, 2024, at 5:00 p.m. Eastern Time to discuss its first quarter 2024 financial results. Investors interested in listening to the conference call are required to register online. A live webcast of the conference call will be available on the “Investors” section of the Company's website at The webcast will be archived on the website following the completion of the call for three months.

Non-GAAP Financial Measures

In addition to reporting financial measures in accordance with generally accepted accounting principles (“GAAP”), Akoya is including in this press release “non-GAAP adjusted gross profit,” “non-GAAP adjusted gross margin,” “non-GAAP operating expense,” and “non-GAAP loss from operations,” all of which are non-GAAP financial measures. Akoya defines non-GAAP adjusted gross profit as gross profit margin adjusted for certain excess and obsolete inventory charges. Non-GAAP adjusted gross margin is defined as non-GAAP adjusted gross profit divided by total revenue. Akoya defines non-GAAP operating expense as operating expense adjusted for impairment and restructuring charges. Akoya defines non-GAAP loss from operations as loss from operations adjusted for certain excess and obsolete inventory charges, impairment, and restructuring charges.

Akoya includes these non-GAAP financial measures because it believes they allow investors to understand and evaluate the Company’s core operating performance and trends. In particular, the exclusion of certain items in calculating non-GAAP adjusted gross profit, non-GAAP adjusted gross margin, non-GAAP operating expense, and non-GAAP loss from operations can provide useful measures for period-to-period comparisons of the Company’s core business. These non-GAAP financial measures have limitations as analytical tools, including the fact that such non-GAAP financial measures may not be comparable to similarly titled measures presented by other companies because other companies may calculate non-GAAP adjusted gross profit, non-GAAP adjusted gross margin, non-GAAP operating expense, and non-GAAP loss from operations differently than Akoya does. For more information regarding these non-GAAP financial measures, see the tables included at the end of this press release.

Forward-Looking Statements

This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our expectations for full year 2024 revenue, our growth prospects, our ability to achieve operating cash flow breakeven, projected timing for achieving operating cash flow breakeven, our expectations regarding our ability to market, sell and meet demand for our products and services, our expectations regarding our current and potential partnerships and collaborations, and other statements regarding our business strategies, use of capital, results of operations, financial and operational performance and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

About Akoya Biosciences

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit

Investor Contact:

Priyam Shah 

Media Contact:

Christine Quern

Condensed Consolidated Balance Sheets (unaudited)
(in thousands)
     March 31, 2024    December 31, 2023
Current assets        
Cash and cash equivalents $ 13,039  $ 83,125 
Marketable securities   48,536    
Accounts receivable, net   13,473    16,994 
Inventories, net   22,988    17,877 
Prepaid expenses and other current assets   3,793    3,794 
Total current assets   101,829    121,790 
Property and equipment, net   8,964    10,729 
Demo inventory, net   726    893 
Intangible assets, net   16,699    17,412 
Goodwill   18,262    18,262 
Operating lease right of use assets, net   5,568    8,365 
Financing lease right of use assets, net   1,348    1,562 
Other non-current assets   1,354    1,356 
Total assets $ 154,750  $ 180,369 
Liabilities and Stockholders’ Equity        
Current liabilities        
Accounts payable, accrued expenses and other current liabilities $ 23,209  $ 25,209 
Current portion of operating lease liabilities   2,654    2,681 
Current portion of financing lease liabilities   718    767 
Deferred revenue   6,612    6,688 
Total current liabilities   33,193    35,345 
Deferred revenue, net of current portion   2,928    3,193 
Long-term debt, net   75,469    75,254 
Contingent consideration liability, net of current portion   4,015    5,765 
Operating lease liabilities, net of current portion   5,713    6,238 
Financing lease liabilities, net of current portion   634    766 
Other long-term liabilities   75    38 
Total liabilities   122,027    126,599 
Total stockholders' equity   32,723    53,770 
Total liabilities and stockholders' equity $ 154,750  $ 180,369 

Consolidated Statements of Operations (unaudited)
(in thousands, except share and per share amounts)
  Three months ended
  March 31,  March 31, 
     2024     2023 
Product revenue $ 12,140  $ 15,524 
Service and other revenue   6,210    5,886 
Total revenue   18,350    21,410 
Cost of goods sold:      
Cost of product revenue   6,723    5,751 
Cost of service and other revenue   3,248    3,366 
Total cost of goods sold   9,971    9,117 
Gross profit   8,379    12,293 
Operating expenses:      
Selling, general and administrative   19,863    23,124 
Research and development   5,554    6,378 
Change in fair value of contingent consideration   179    227 
Impairment   2,971    
Restructuring   1,397    
Total operating expenses   29,964    29,729 
Loss from operations   (21,585)   (17,436)
Other income (expense):      
Interest expense   (2,612)   (2,054)
Interest income   937    765 
Other expense, net   (161)   (48)
Loss before provision for income taxes   (23,421)   (18,773)
Provision for income taxes   (63)   (29)
Net loss $ (23,484) $ (18,802)
Net loss per share attributable to common stockholders, basic and diluted $ (0.48) $ (0.49)
Weighted-average shares outstanding, basic and diluted   49,188,170    38,326,024 

Gross Profit to Non-GAAP Adjusted Gross Profit Reconciliation and Calculation of Gross Margin and Non-GAAP Adjusted Gross Margin (unaudited)
(in thousands)
  Three months ended
  March 31,  March 31, 
     2024     2023 
Total revenue $ 18,350  $ 21,410 
Gross profit   8,379    12,293 
Provision for excess and obsolete inventories - product discontinuation and lease exit inventory charges  2,045    
Non-GAAP adjusted gross profit $ 10,424  $ 12,293 
Gross margin  46%   57% 
Non-GAAP adjusted gross margin  57%   57% 

Operating Expense to Non-GAAP Operating Expense Reconciliation (unaudited)
(in thousands)
  Three months ended
  March 31,  March 31, 
     2024     2023
Operating expenses $ 29,964  $ 29,729 
Impairment  (2,971)   
Restructuring  (1,397)   
Non-GAAP operating expenses $ 25,596  $ 29,729 

Loss From Operations to Non-GAAP Loss From Operations Reconciliation (unaudited)
(in thousands)
  Three months ended
  March 31,  March 31, 
     2024     2023 
Loss from operations $ (21,585) $ (17,436)
Provision for excess and obsolete inventories - product discontinuation and lease exit inventory charges  2,045    
Impairment  2,971    
Restructuring  1,397    
Non-GAAP loss from operations $ (15,172) $ (17,436)

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.